The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsActivity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolidAntimicrobial resistance: the example of Staphylococcus aureusMechanisms of vancomycin resistance in Staphylococcus aureusStructure-based mechanism of lipoteichoic acid synthesis by Staphylococcus aureus LtaSMolecular Basis for the Role of Staphylococcus aureus Penicillin Binding Protein 4 in Antimicrobial ResistanceVancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineagesEnterococcus faecalis phosphomevalonate kinase.Development of a novel targeting system for lethal photosensitization of antibiotic-resistant strains of Staphylococcus aureus.Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.Vancomycin-resistant gram-positive cocci isolated from the saliva of wild songbirds.Glycans in pathogenic bacteria--potential for targeted covalent therapeutics and imaging agents.Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureusCharacterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureusMolecular epidemiology of methicillin-resistant Staphylococcus aureus in Zurich, Switzerland (2003): prevalence of type IV SCCmec and a new SCCmec element associated with isolates from intravenous drug usersUnderestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus.Methicillin and Vancomycin Resistant S. aureus in Hospitalized Patients.Total synthesis of [Ψ[C(═NH)NH]Tpg(4)]vancomycin and its (4-chlorobiphenyl)methyl derivative: impact of peripheral modifications on vancomycin analogues redesigned for dual D-Ala-D-Ala and D-Ala-D-Lac binding.Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance.Genetics of antimicrobial resistance in Staphylococcus aureus.Transcriptomic and functional analysis of an autolysis-deficient, teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus.Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.Nationwide surveillance for Staphylococcus aureus with reduced susceptibility to vancomycin in KoreaTotal syntheses and initial evaluation of [Ψ[C(═S)NH]Tpg⁴]vancomycin, [Ψ[C(═NH)NH]Tpg⁴]vancomycin, [Ψ[CH₂NH]Tpg⁴]vancomycin, and their (4-chlorobiphenyl)methyl derivatives: synergistic binding pocket and peripheral modifications for the glycopeptidePrevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care centerDaptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care unitsIn vitro activities of 18 antimicrobial agents against Staphylococcus aureus isolates from the Institut Pasteur of MadagascarMolecular diagnostics of clinically important staphylococci.Redesign of glycopeptide antibiotics: back to the futureA multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA).Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureuMRSA--what is it, and how do we deal with the problem?Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA).Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.
P2860
Q24646677-C1C6A867-C994-4F70-8756-A5AC1A7B5205Q24650535-9591ED77-07FB-4D73-82DE-48FA960575E4Q24676363-9D997ED5-1FC7-41D1-9DD1-2769F94BB428Q26829312-5EE5FA36-BBE3-4B93-A3B4-5C3EC8FCB969Q27653515-CA92DDC8-1460-4EE1-B25A-537FFE550E85Q27657968-4F113418-4FBC-47CB-B9FE-EB17C8A7CE74Q30341876-3A5D57E2-B340-48CB-9843-D5D50B634EE0Q33213455-32262634-CF44-4B5F-8E57-6D419C63162CQ33222429-89E85D37-5D36-411B-AF9D-E953FF037018Q33321447-4CC00D9E-6C69-400C-9420-4E0501600F54Q33555775-BF081934-0A34-4B16-94FE-5E118570E255Q33699395-AB4A6FA5-6AFD-45A5-A0EF-E3E86DFCCD73Q33725733-DADD6AF5-67D6-4358-82F0-21AD4B94B8D9Q33935282-C68FB649-7B1B-4821-AB94-068FBB6CEE1EQ34057548-9E6FDB16-425D-4C61-984E-736FF775A174Q34073497-81EEFC56-ADB8-4185-856B-966D6251569AQ34108614-AF41D838-AD42-45DA-9C69-D14D51C65D8FQ34141289-3A750C6D-4176-4BEC-9564-5C4AC8CF3B43Q34142160-D3C19B03-78CA-4893-A151-1923287C8542Q34282738-8BCF8509-56C3-4F80-BE48-67667D61BAFCQ34402839-7F12FD9C-1A23-4619-9909-23483ABF482DQ34596835-DB28F65C-0DBE-4E0F-981B-5690DF6871FAQ34721614-95DC1BBD-79E4-4E19-997C-B01AB4127538Q34984662-6838FDF7-6082-4067-9FDA-0CE83C762810Q35023285-8FEBC5B9-2C0F-4F1B-8918-028EE1F385CAQ35023343-FFB11AF7-691B-4CEB-BCB0-47937218F60BQ35026306-6663FB8C-3B1C-4693-B088-06A5652F5E71Q35224649-0FA88A40-EEA5-4E13-B3CC-44BC9A7F8B01Q35784453-12CAC54D-F83C-41C0-89C6-5E2279A91B71Q35802607-9AE18DF9-C1E0-4609-9D54-D394A5FBCC64Q35806369-BC6164D9-101F-46E6-9FD1-772D917E9878Q35819831-0E72B060-5B46-49A4-B7C8-2E57B43F5705Q35840646-9B92900B-CA36-46E9-91F5-6AACAE050D1AQ35941369-1DEE8BD4-636B-4C04-B10A-353F507F8724Q35973511-DBBB7A29-2874-41EB-8B65-BCD403963C85Q36083140-11F6FC35-8AEC-48CB-AF0D-38A6D26D744EQ36098762-4F1B60FE-9828-4C65-9296-0D6DCEBACE84Q36150828-ED9EDA6E-1088-4B55-AAD1-E51944D54267Q36315377-0E1F441B-C096-478B-BBA7-9576C76077C7Q36328966-F0E93BEC-9CFE-4419-A0A9-FE9C283CB7FA
P2860
The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.
@ast
The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.
@en
The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.
@nl
type
label
The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.
@ast
The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.
@en
The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.
@nl
prefLabel
The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.
@ast
The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.
@en
The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.
@nl
P1476
The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus
@en
P2093
Robin A Howe
P304
P356
10.1146/ANNUREV.MICRO.56.012302.160806
P577
2002-01-30T00:00:00Z